首页> 美国卫生研究院文献>Liebert Funded Articles >Perspectives on In Vitro to In Vivo Extrapolations
【2h】

Perspectives on In Vitro to In Vivo Extrapolations

机译:体外到体内外推的观点

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Quantitative to extrapolation (QIVIVE) is broadly considered a prerequisite bridge from findings to a dose paradigm. Quality and relevance of cell systems are the first prerequisite for QIVIVE. Information-rich and mechanistic endpoints (biomarkers) improve extrapolations, but a sophisticated endpoint does not make a bad cell model a good one. The next need is reverse toxicokinetics (TK), which estimates the dose necessary to reach a tissue concentration that is active . The Johns Hopkins Center for Alternatives to Animal Testing (CAAT) has created a roadmap for animal-free systemic toxicity testing, in which the needs and opportunities for TK are elaborated, in the context of different systemic toxicities. The report was discussed at two stakeholder forums in Brussels in 2012 and in Washington in 2013; the key recommendations are summarized herein. Contrary to common belief and the Paracelsus paradigm of everything is toxic, the majority of industrial chemicals do not exhibit toxicity. Strengthening the credibility of negative results of alternative approaches for hazard identification, therefore, avoids the need for QIVIVE. Here, especially the combination of methods in integrated testing strategies is most promising. Two further but very different approaches aim to overcome the problem of modeling complexity: The movement aims to reproduce large parts of living organism's complexity via microphysiological systems, that is, organ equivalents combined by microfluidics. At the same time, the Toxicity Testing in the 21st Century (Tox-21c) movement aims for mechanistic approaches (adverse outcome pathways as promoted by Organisation for Economic Co-operation and Development (OECD) or pathways of toxicity in the Human Toxome Project) for high-throughput screening, biological phenotyping, and ultimately a systems toxicology approach through integration with computer modeling. These 21st century approaches also require 21st century validation, for example, by evidence-based toxicology. Ultimately, QIVIVE is a prerequisite for extrapolating Tox-21c such approaches to human risk assessment.
机译:定量外推(QIVIVE)被广泛认为是从发现到剂量范式的前提桥梁。细胞系统的质量和相关性是QIVIVE的首要前提。信息丰富且机械的端点(生物标记物)可改善推断,但复杂的端点并不能使坏细胞模型成为一个好模型。下一个需求是反向毒物动力学(TK),它可以估算达到有效组织浓度所需的剂量。约翰霍普金斯大学动物测试替代中心(CAAT)已制定了无动物系统毒性测试的路线图,其中根据不同的系统毒性阐述了传统知识的需求和机会。该报告在2012年于布鲁塞尔和2013年在华盛顿的两个利益相关者论坛上进行了讨论。关键建议总结如下。与普遍的看法相反,所有东西的Paracelsus范例都是有毒的,大多数工业化学品都没有毒性。因此,增强了替代方法对危害进行识别的负面结果的可信度,从而避免了对QIVIVE的需求。在这里,尤其是综合测试策略中方法的组合是最有前途的。两种另外但非常不同的方法旨在克服复杂性建模的问题:该运动旨在通过微生理系统,即由微流体结合的器官等效物,再现生物体的大部分复杂性。同时,“ 21世纪的毒性测试(Tox-21c)”运动旨在采用机械方法(经济合作与发展组织(OECD)倡导的不良结果途径或人类毒理学项目中的毒性途径)用于高通量筛选,生物表型分析以及最终通过与计算机建模集成的系统毒理学方法。这些21世纪的方法还需要21世纪的验证,例如,基于证据的毒理学。最终,QIVIVE是推断Tox-21c这样的人类风险评估方法的前提。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号